Pfizer (NYSE:PFE) is one of the globe's biggest drugmakers, and its stock is a staple in dividend portfolios.
However, patent expiration of key drugs has shaved billions off its top line, putting pressure on Pfizer to use its substantial cash position to bolster its research pipeline. As a result, dividend investors are right to question whether sliding sales threaten its dividend payout.
In the following slideshow, you'll learn more about Pfizer's patent headwind and how Pfizer compares to industry peers like AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK) when it comes to dividend payouts.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not own positions in the companies mentioned.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.